|Articles|July 1, 2004

Phase III study eyes intravitreal therapy for exudative AMD

Anti-VEGF monoclonal antibody fragment improves vision, reduce fluorescein angiographic leakage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME